

Trametinib (DMSO solvate)

Catalog No: tcsc0061

Available Sizes

Size: 10mg
Size: 50mg
Size: 200mg
Size: 500mg
Size: 500mg
Size: 1g
Size: 2g
Size: 2g
Size: 5g
Specifications

CAS No: 1187431-43-1

Formula:

 $\mathrm{C_{28}H_{29}FIN_5O_5S}$

Pathway:

MAPK/ERK Pathway

Target:

MEK

Purity / Grade:

>98%

Solubility:

Copyright 2021 Taiclone Biotech Corp.



DMSO : 69 mg/mL (99.49 mM; Need ultrasonic)

Alternative Names:

GSK-1120212 DMSO solvate;Trametinib;JTP-74057;GSK1120212

Observed Molecular Weight:

693.53


Product Description

Trametinib DMSO solvate is a potent **MEK** inhibitor that specifically inhibits MEK1/2, with an **IC₅₀** value of about 2 nM.

IC50 & Target: IC50: 2 nM (MEK1/2)^[1]

In Vitro: In BRAF mutant SK-MEL-28 cells and KRAS mutant HCT116 cells, Trametinib (GSK1120212) DMSO solvate causes dose-dependent inhibition of ERK1/2 phosphorylation as well as dose-dependent growth inhibition. In both SK-MEL-28 and HCT116 cells, Trametinib DMSO solvate inhibits 50% p-ERK1/2 at nearly equivalent concentrations (0.8 and 1.8 nM, respectively). However, as the slopes of the curves reflect, in SK-MEL-28 cells, Trametinib DMSO solvate inhibits 90% p-ERK1/2 at a lower concentration (3.4 nM) than in HCT116 (33.3 nM). Furthermore, in both cell lines, 50% growth inhibition is only achieved at concentrations Trametinib DMSO solvate that produces near complete ERK1/2 inhibition (85 and 90%, respectively)^[2].

In Vivo: Trametinib (GSK1120212) DMSO solvate is evaluated in vivo in an A549 (KRAS mutant cell line) xenograft model, orally dosing daily for 21 days (qd×21). In this study, near complete tumor growth inhibition is observed at 5.0 and 2.5 mg/kg [92 and 87% tumor growth inhibition (TGI), respectively] and to a lesser degree at 0.5 and 0.1 mg/kg (62 and 58% TGI). Although 5 mg/kg is the maximally tolerated dose (MTD) in this study, 3 mg/kg is the typically observed MTD. Dose-dependent antitumor activity with Trametinib DMSO solvate treatment has been similarly reported for several other KRAS and BRAF mutant tumor models^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.